Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Study protocol

TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial

Authors: M. Lagendijk, E. L. Vos, A. H. J. Koning, M. G. M. Hunink, J. P. Pignol, E. M. L. Corten, C. de Monye, C. H. M. van Deurzen, J. H. van Dam, W. W. Vrijland, C. M. E. Contant, C. Verhoef, W. van Lankeren, L. B. Koppert

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Cosmetic result following breast conserving surgery (BCS) for cancer influences quality of life and psychosocial functioning in breast cancer patients. A preoperative prediction of expected cosmetic result following BCS is not (yet) standard clinical practice and therefore the choice for either mastectomy or BCS is still subjective. Recently, we showed that tumour volume to breast volume ratio as well as tumour location in the breast are independent predictors of superior cosmetic result following BCS. Implementation of a prediction model including both factors, has not been studied in a prospective manner. This study aims to improve cosmetic outcome by implementation of a prediction model in the treatment decision making for breast cancer patients opting for BCS.

Methods/design

Multicentre, single-blinded, randomized controlled trial comparing standard preoperative work-up to a preoperative work-up with addition of the prediction model. Tumour volume to breast volume ratio and tumour location in the breast will be used to predict cosmetic outcome in invasive breast cancer patients opting for BCS. Three dimensional (3D)-ultrasonography will be used to measure the tumour volume to breast volume ratio needed for the prediction model. Sample size was estimated based on a 14% improvement in incidence of superior cosmetic result one year after BCS (71% in the control group versus 85% in the intervention group). Primarily cosmetic outcome will be evaluated by a 6-member independent panel. Secondary endpoints include; (1) patient reported outcome measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5 L (2) cosmetic outcome as assessed through the BCCT.core software, (3) radiation-induced reaction (4) surgical treatment performed, (5) pathological result and (6) cost-effectiveness. Follow-up data will be collected for 3 years after surgery or finishing radiotherapy.

Discussion

This randomized controlled trial examines the value of a preoperative prediction model for the treatment-decision making. It aims for a superior cosmetic result in breast cancer patients opting for BCS. We expect improvement of patients’ quality of life and psychosocial functioning in a cost-effective way.

Trial registration

Prospectively registered, February 17th 2015, at ‘Nederlands Trialregister - NTR4997’.
Appendix
Available only for authorised users
Literature
1.
Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef
2.
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–65.CrossRefPubMed
3.
Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefPubMed
4.
Fisher B, Anderson S, Bryant J. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;
5.
6.
Waljee JF, Hu ES, Ubel PA, Smith DM, Newman LA, Alderman AK. Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(20):3331–7.CrossRef
7.
Hau E, Browne L, Capp A, Delaney GP, Fox C, Kearsley JH, et al. The impact of breast cosmetic and functional outcomes on quality of life: long-term results from the St. George and Wollongong randomized breast boost trial. Breast Cancer Res Treat. 2013;139(1):115–23.CrossRefPubMed
8.
Aaronson N, Bartelink H, Vandongen JA, Vandam F. Evaluation of breast conserving therapy: clinical, methodological and psychosocial perspectives. Eur J Surg Oncol. 1988;14(2):133–40.PubMed
9.
Haloua MH, Krekel NM, Winters HA, Rietveld DH, Meijer S, Bloemers FW, et al. A systematic review of oncoplastic breast-conserving surgery: current weaknesses and future prospects. Ann Surg. 2013;257(4):609–20.CrossRefPubMed
10.
Vos EL, Koning AHJ, Obdeijn I-M, van Verschuer VMT, Verhoef C, van der Spek PJ, et al. Preoperative prediction of cosmetic results in breast conserving surgery. J Surg Oncol. 2014:n/a-n/a.
11.
Wang HT, Barone CM, Steigelman MB, Kahlenberg M, Rousseau D, Berger J, et al. Aesthetic outcomes in breast conservation therapy. Aesthet Surg J. 2008;28(2):165–70.CrossRefPubMed
12.
Lin X, Wang J, Han F, Fu J, Li A. Analysis of eighty-one cases with breast lesions using automated breast volume scanner and comparison with handheld ultrasound. Eur J Radiol. 2012;81(5):873–8.CrossRefPubMed
13.
Clauser P, Como G, Girometti R, Zuiani C, Londero V, Bazzocchi M. Comparison between different imaging techniques in the evaluation of malignant breast lesions: can 3D ultrasound be useful? La radiologia medica. 2013;119(4):240–8.CrossRefPubMed
14.
Wojcinski S, Farrokh A, Hille U, Wiskirchen J, Gyapong S, Soliman AA, et al. The automated breast volume scanner (ABVS): initial experiences in lesion detection compared with conventional handheld B-mode ultrasound: a pilot study of 50 cases. Int J Womens Health. 2011;3:337–46.CrossRefPubMedPubMedCentral
15.
Baken L, van Gruting IMA, Steegers EAP, van der Spek PJ, Exalto N, Koning AHJ. Design and validation of a 3D virtual reality desktop system for sonographic length and volume measurements in early pregnancy evaluation. J Clin Ultrasound. 2015;43(3):164–70.CrossRefPubMed
16.
Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345–53.CrossRefPubMed
17.
Cardoso MJ, Cardoso JS, Vrieling C, Macmillan D, Rainsbury D, Heil J, et al. Recommendations for the aesthetic evaluation of breast cancer conservative treatment. Breast Cancer Res Treat. 2012;135(3):629–37.CrossRefPubMed
18.
Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1979;5(2):257–61.CrossRefPubMed
19.
Cardoso JS, Cardoso MJ. Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment. Artif Intell Med. 2007;
20.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). International Journal of Radiation Oncology*Biology*Physics. 1995;31(5):1341–6.
21.
Peterson D, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim DH, et al. Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. Int J Radiat Oncol Biol Phys. 2015;91(5):968–76.CrossRefPubMed
22.
Kim MK, Kim T, Moon HG, Kim K, Kim J. Effect of cosmetic outcome on quality of life after breast cancer surgery. Eur J Surg Oncol: Jin US; 2014.
23.
Haloua MH, Krekel, NM, Jacobs GJ, Zonderhuis, B, Bouman, MB, Buncamper, ME, Niessen, FB, Winters, HA, Terwee, C, Meijer, S, van den Tol, MP. Cosmetic Outcome Assessment following Breast-Conserving Therapy: A comparison between BCCT.core Software and Panel Evaluation. Int J Breast Cancer. 2014.
24.
Aaronson NK, Ahmedzai S, Bregman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institue. 1993;
25.
McLachlan SA, Devins GM, Goodwin PJ. Validation of the European Organization for Research and Treatment of cancer quality of life questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer. 1998;
26.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC radiotherapy and breast cancer cooperative groups. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2000;55(3):219–32.CrossRef
27.
Cardoso MJ, Santos AC, Cardoso J, Barros H, De Oliveira MC. Choosing observers for evaluation of aesthetic results in breast cancer conservative treatment. Int J Radiat Oncol Biol Phys. 2005;61(3):879–81.CrossRefPubMed
28.
Fortin AJ, Cheang M, Latosinsky S. Cosmetic outcomes following breast conservation therapy: in search of a reliable scale. Breast Cancer Res Treat. 2006;100 (1):65 –70. Fortin AJ, Cheang M, Latosinsky S. Cosmetic outcomes following breast conservation therapy: in search of a reliable scale. Breast Cancer Res Treat 2006;100(1):65–70.
29.
Cardoso JS, Cardoso MJ. Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment. Artif Intell Med. 2007;40(2):115–26.CrossRefPubMed
30.
Cardoso MJ, Cardoso J, Amaral N, Azevedo I. Turning subjective into objective: The BCCT. core software for evaluation of cosmetic results in breast cancer conservative treatment. The Breast. 2007.
31.
Cardoso MJ, Cardoso JS, Wild T, Krois W, Fitzal F. Comparing two objective methods for the aesthetic evaluation of breast cancer conservative treatment. Breast Cancer Res Treat. 2008;116(1):149–52.CrossRefPubMed
Metadata
Title
TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial
Authors
M. Lagendijk
E. L. Vos
A. H. J. Koning
M. G. M. Hunink
J. P. Pignol
E. M. L. Corten
C. de Monye
C. H. M. van Deurzen
J. H. van Dam
W. W. Vrijland
C. M. E. Contant
C. Verhoef
W. van Lankeren
L. B. Koppert
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3280-y

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Study protocol

Life situation and psychosocial care of adolescent and young adult (AYA) cancer patients – study protocol of a 12-month prospective longitudinal study

Research article

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples

Review

Molecular chess? Hallmarks of anti-cancer drug resistance

Research article

Innovative dressing and securement of tunneled central venous access devices in pediatrics: a pilot randomized controlled trial

Research article

Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma

Research article

Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits